Cell Death and Disease (Jul 2023)

Flt1 produced by lung endothelial cells impairs ATII cell transdifferentiation and repair in pulmonary fibrosis

  • Maria Concetta Volpe,
  • Giulio Ciucci,
  • Giulia Zandomenego,
  • Roman Vuerich,
  • Nadja Anneliese Ruth Ring,
  • Simone Vodret,
  • Francesco Salton,
  • Pietro Marchesan,
  • Luca Braga,
  • Thomas Marcuzzo,
  • Rossana Bussani,
  • Andrea Colliva,
  • Silvano Piazza,
  • Marco Confalonieri,
  • Serena Zacchigna

DOI
https://doi.org/10.1038/s41419-023-05962-2
Journal volume & issue
Vol. 14, no. 7
pp. 1 – 13

Abstract

Read online

Abstract Pulmonary fibrosis is a devastating disease, in which fibrotic tissue progressively replaces lung alveolar structure, resulting in chronic respiratory failure. Alveolar type II cells act as epithelial stem cells, being able to transdifferentiate into alveolar type I cells, which mediate gas exchange, thus contributing to lung homeostasis and repair after damage. Impaired epithelial transdifferentiation is emerging as a major pathogenetic mechanism driving both onset and progression of fibrosis in the lung. Here, we show that lung endothelial cells secrete angiocrine factors that regulate alveolar cell differentiation. Specifically, we build on our previous data on the anti-fibrotic microRNA-200c and identify the Vascular Endothelial Growth Factor receptor 1, also named Flt1, as its main functional target in endothelial cells. Endothelial-specific knockout of Flt1 reproduces the anti-fibrotic effect of microRNA-200c against pulmonary fibrosis and results in the secretion of a pool of soluble factors and matrix components able to promote epithelial transdifferentiation in a paracrine manner. Collectively, these data indicate the existence of a complex endothelial-epithelial paracrine crosstalk in vitro and in vivo and position lung endothelial cells as a relevant therapeutic target in the fight against pulmonary fibrosis.